Meet the One Million Strong – Ashleigh T. from South Carolina

Be a part of One Million Strong and tell us how colorectal cancer has impacted your life! Share your story now!   Meet Ashleigh Ashleigh Tucker , Family Charleston, SC Ashleigh’s Story In October 2002 my dad was diagnosed with stage 4 colorectal cancer, he was only 33. He had three small children ages 10, seven, and four,…  Read More

ACA Mandates Insurance Coverage for Clinical Trials

By January 1, all insurers will be required to cover routine care for patients enrolled in clinical trials. (Typically any experimental care is provided at no cost to the patient.) “This should be seen as a step forward for the U.S. oncology community,” wrote Dr. Y-Ning Wong in the ASCO Daily News from the American Society of…  Read More

Colon Cancer Prevention Trial Seeking New Patients

Can drugs used to help lower cholesterol also keep colon cancer from returning?  Researchers at the National Surgical Adjuvant Breast and Bowel Project (NSABP) are seeking patients for a one-year clinical trial to determine if cholesterol-lowering drugs (statins) might help prevent the growth of precancerous (adenomatous) polyps and/or recurrent colorectal cancer. The NSABP trial is sponsored by…  Read More

National polyp prevention trial needs participants

  Do cholesterol-lowering drugs help prevent CRC? You might be able to help answer that question. A national research project needs people who have been treated for early-stage (stage I or II) colorectal cancer in the past year. There have been tantalizing hints that cholesterol-lowering drugs (statins) might help prevent the growth of precancerous (adenomatous) polyps…  Read More

New Trial Looks to Reduce Recurrence and Neuropathy for Stage III Patients

If you are diagnosed with stage III colon cancer, you will probably receive about six months of treatment with FOLFOX after surgery. Research shows that this treatment regimen helps prevent recurrence for some – but not all – patients with stage III colon cancer.  A clinical trial has been launched to answer two questions about this…  Read More

X-PECT Trial is Fully Enrolled

The X-PECT phase III clinical trial has finished recruiting over 430 patients, evaluating perifosine treatment for patients with advanced colorectal cancer who have exhausted standard treatments. The trial compares the effectiveness of adding perifosine to Xeloda® (capecitabine). Led by Johanna Bendell, M.D., from the Sarah Cannon Research Institute in Nashville, TN, the trial is being conducted…  Read More